Free Trial

1,033 Shares in Amgen Inc. (NASDAQ:AMGN) Acquired by Alpine Bank Wealth Management

Amgen logo with Medical background

Alpine Bank Wealth Management purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 1,033 shares of the medical research company's stock, valued at approximately $322,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in AMGN. Capital World Investors lifted its position in shares of Amgen by 1,292.0% in the fourth quarter. Capital World Investors now owns 6,495,710 shares of the medical research company's stock worth $1,693,042,000 after buying an additional 6,029,058 shares during the last quarter. Norges Bank acquired a new stake in shares of Amgen in the fourth quarter worth about $1,541,991,000. GAMMA Investing LLC lifted its position in shares of Amgen by 43,573.5% in the first quarter. GAMMA Investing LLC now owns 3,661,589 shares of the medical research company's stock worth $1,140,768,000 after buying an additional 3,653,205 shares during the last quarter. Capital International Investors lifted its position in shares of Amgen by 40.1% in the fourth quarter. Capital International Investors now owns 12,212,065 shares of the medical research company's stock worth $3,182,843,000 after buying an additional 3,495,503 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Amgen by 25.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 13,205,604 shares of the medical research company's stock worth $3,441,909,000 after purchasing an additional 2,672,975 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on AMGN shares. Piper Sandler reissued an "overweight" rating and set a $328.00 price objective on shares of Amgen in a research report on Friday. Wall Street Zen raised Amgen from a "buy" rating to a "strong-buy" rating in a research report on Sunday, May 18th. Cantor Fitzgerald reissued a "neutral" rating and set a $305.00 price objective on shares of Amgen in a research report on Tuesday. Johnson Rice set a $294.00 price objective on Amgen in a research report on Wednesday, March 5th. Finally, Guggenheim started coverage on Amgen in a research report on Tuesday, May 20th. They set a "neutral" rating and a $288.00 price objective for the company. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, eight have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $307.82.

View Our Latest Analysis on AMGN

Insider Activity

In related news, SVP Rachna Khosla sold 1,500 shares of the stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $289.68, for a total transaction of $434,520.00. Following the sale, the senior vice president now directly owns 8,162 shares in the company, valued at $2,364,368.16. This represents a 15.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.76% of the company's stock.

Amgen Price Performance

Shares of AMGN stock traded down $1.98 during trading hours on Friday, hitting $277.13. The company had a trading volume of 2,894,198 shares, compared to its average volume of 2,833,059. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85. The firm has a market capitalization of $149.02 billion, a price-to-earnings ratio of 25.29, a PEG ratio of 2.52 and a beta of 0.51. The firm's fifty day moving average is $281.02 and its 200 day moving average is $286.02. The company has a debt-to-equity ratio of 8.70, a quick ratio of 0.88 and a current ratio of 1.17.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, beating the consensus estimate of $4.18 by $0.72. Amgen had a return on equity of 176.11% and a net margin of 17.39%. The company had revenue of $8.15 billion for the quarter, compared to analyst estimates of $8.05 billion. During the same period in the prior year, the company posted $3.96 EPS. The company's revenue was up 9.4% compared to the same quarter last year. On average, sell-side analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.

About Amgen

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Featured Articles

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Should You Invest $1,000 in Amgen Right Now?

Before you consider Amgen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.

While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore
AI Stocks Are Printing Money — These 3 Are Just Getting Started

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines